Outcome predictions for patients with metastatic prostate cancerSMALETZ, Oren; SCHER, Howard I.Seminars in urologic oncology. 2002, Vol 20, Num 2, pp 155-163, issn 1081-0943Article

Potential for drug interactions in hospitalized cancer patientsPIMENTA RIECHELMANN, Rachel; MOREIRA, Frederico; SMALETZ, Oren et al.Cancer chemotherapy and pharmacology. 2005, Vol 56, Num 3, pp 286-290, issn 0344-5704, 5 p.Article

Estimating survival benefit in castrate metastatic prostate cancer: Decision making in proceeding to a definitive phase III trialVERBEL, David Andrew; KELLY, W. Kevin; SMALETZ, Oren et al.Urology (Ridgewood, NJ). 2003, Vol 61, Num 1, pp 142-144, issn 0090-4295, 3 p.Article

High-dose calcitriol, zoledronate, and dexamethasone for the treatment of progressive prostate carcinomaMORRIS, Michael J; SMALETZ, Oren; ZHU, Andrew et al.Cancer. 2004, Vol 100, Num 9, pp 1868-1875, issn 0008-543X, 8 p.Article

Rapid androgen cycling astreatment for patients with prostate cancerFELTQUATE, David; NORDQUIST, Luke; SCHER, Howard I et al.Clinical cancer research. 2006, Vol 12, Num 24, pp 7414-7421, issn 1078-0432, 8 p.Article

Nomogram for overall survival of patients with progressive metastatic prostate cancer after castrationSMALETZ, Oren; SCHER, Howard I; SMALL, Eric J et al.Journal of clinical oncology. 2002, Vol 20, Num 19, pp 3972-3982, issn 0732-183X, 11 p.Article